|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis.
|
28331226 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia.
|
19691103 |
2009 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 and SRSF2 mutation were not associated with increased leukemia transformation.
|
29970342 |
2018 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
JAK2 clinical mutations cause myeloproliferative neoplasms and leukemia, and the mutations strongly concentrate in the regulatory pseudokinase domain Janus kinase homology (JH) 2.
|
30092288 |
2019 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A search for additional mutations identified alterations of RUNX1, WT1, TP53, CBL, NRAS, and TET2, without significant differences between JAK2-mutant and wild-type leukemias.
|
20008300 |
2010 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
|
9360930 |
1997 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aberrant activation of the JAK-STAT pathway has been implicated in tumor formation; for example, constitutive activation of JAK2 kinase or the enforced expression of STAT5 induces leukemia in mice.
|
15578097 |
2004 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia.
|
21712540 |
2011 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Analysis of the exon 12 and 14 mutations of the JAK2 gene in Philadelphia chromosome-positive leukemia.
|
17851549 |
2008 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Constitutive activation of Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling has an important role in the oncogenesis of myeloproliferative neoplasms (MPNs) and leukemia.
|
23111066 |
2013 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutively activated mutants of the non-receptor tyrosine kinases (TK) ABL1 (Abelson murine leukemia viral (v-abl) homolog (1) protein) and JAK2 (JAnus Kinase 2 or Just Another Kinase 2) play a central role in the pathogenesis of clinically and morphologically distinct chronic myeloproliferative disorders but are also found in some cases of de novo acute leukemia and lymphoma.
|
18528425 |
2008 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment.
|
23432162 |
2013 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
|
29940115 |
2018 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
CTD_human |
Essential thrombocythemia: past and present.
|
19636672 |
2009 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fusion of the TEL gene on 12p13 to the JAK2 tyrosine kinase gene on 9p24 has been found in human leukemia.
|
11278610 |
2001 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ginsenoside Rg1 induces apoptosis through inhibition of the EpoR-mediated JAK2/STAT5 signalling pathway in the TF-1/ Epo human leukemia cell line.
|
24761846 |
2014 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Having both a tyrosine kinase-activating rearrangement and genomic lesions affecting lymphoid transcription factors suggested that the leukemia was of the Philadelphia chromosome (Ph)/BCR-ABL1-like ALL subtype and that JAK2 inhibitors might be able to overcome this aggressive ALL with SPAG9-JAK2.
|
25951811 |
2015 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative leukemia virus gene is mutated.
|
27686378 |
2017 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In particular, gain-of-function mutations in the <i>JAK</i> genes, most frequently, V617F in the pseudokinase domain of JAK2, have been mapped in patients with blood disorders, including myeloproliferative neoplasms and leukemias.
|
29379470 |
2017 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this report, we proposed that miRNA-101 targets Jak2 mRNA and regulates its expression and induces K562 leukemia cell apoptosis.
|
27517565 |
2016 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Moreover, JAK2 V617F mutations in CBF leukemias were associated with an aggressive clinical course with 80% of the patients relapsing.
|
17229652 |
2007 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs).
|
21326037 |
2011 |
|
leukemia
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
|
16557239 |
2006 |
|
leukemia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Negative regulation of JAK2 by H3K9 methyltransferase G9a in leukemia.
|
22801367 |
2012 |
|
leukemia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pre-TCR signaling synergizes with TEL-JAK2 to transform immature thymocytes and initiate leukemogenesis as shown by (1) the delayed leukemia onset in Rag2-, CD3epsilon- and pTalpha-deficient mice, (2) the occurrence of recurrent chromosomal alterations in pre-TCR-deficient leukemia, and (3) the correction of delayed leukemia onset in Rag2-deficient TEL-JAK2 mice by an H-Y TCRalphabeta transgene that mimics pre-TCR signaling.
|
17192390 |
2007 |